Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!
A complete application consists of:
All documents must be in English or include an official English translation.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.
*Applications will be reviewed on a rolling-basis, and this opportunity will remain open until filled.
A research opportunity is currently available in the Office of Vaccines Research and Review (OVRR) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The ongoing research performed involves study of SARS-CoV-2, Influenza, Ebola, and Respiratory Syncytial Virus (RSV). We are presently addressing humoral immune responses following infection and vaccination in humans. This information is then used for development and evaluation of vaccines against these viral diseases.
Emphasis is on understanding the role of adjuvants and different vaccine modalities in eliciting broadly cross-reactive protective antibodies. The advanced techniques developed in the lab includes whole genome gene-fragment phage display libraries (GFPDL), high throughput Surface plasmon resonance (SPR), protein production, development of new in vitro and in vivo methods, vaccine development and animal challenge studies.
Anticipated Appointment Start Date: As soon as a qualified candidate is identified; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should have received a bachelor's, master's or doctoral degree in one of the relevant fields, or be currently pursuing one of the degrees with completion by the end of July 2021. Degree must have been received within the past five years.
Candidates with research experience in SPR, phage display, virology, or recombinant protein/antibody production are encouraged to apply.
Have you lived in the United States for at least 36 out of the past 60 months? (36 months do not have to be consecutive.)